Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 22;13:1019702. doi: 10.3389/fonc.2023.1019702

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Huang, Chen, Hu, Hu, Wang and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Case 1 patient achieved PR after the treatment. (A–E) CT images showing the patient’s baseline disease (left panel) and response to treatment (right panel). (A, B) Diffuse thickened gastric wall significantly thinned after the treatment. (C) Pleural effusion indicated the left lung metastasis, and it was absorbed after the treatment. (D) Virchow’s nodes were slightly reduced in size. (E) Retroperitoneal lymph nodes shrunk after the treatment. (F–H) Dynamic monitoring of Fbg level, FDP, platelet counts, PT, and APTT, suggested that the coagulation function was restored. (I) Dynamic monitoring of tumor markers during the treatment. (J) Timeline of the treatment. The patient discontinued PD-1 inhibitors on 29 June and received chemotherapy only, and DIC relapsed after 2 months. PR, partial response; Fbg, fibrinogen; FDP, fibrin degradation product; PT, prothrombin time; APTT, activated partial thromboplastin time.